ClinicalTrials.gg
RecruitingNCT07033598PROSPERAUpdated Aug 18, 2026

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

A Phase 2 interventional study of Pacritinib and Hydroxyurea in Leukemia, Myelomonocytic, Chronic, sponsored by Theradex. Recruiting at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Theradex · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States — 48 open to participants now, 81 under way, 3 of them phase 3. Leukemia, Myelomonocytic, Chronic · United States.

Planned enrollment
115th of 370
66 · median 37
Started
2026
with 8 others
Phase 2
154 of 441
18 open now
Primary completion
2028-07
later than 65 of 80 live
Registered
434th of 441
by date

Among the 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States, this one is the 115th largest by planned enrollment of the 370 interventional ones that give a count, is one of 9 that started in 2026, is one of 154 in phase 2, reaches primary completion later than 65 of the 80 other live ones, and was the 434th registered.

Leukemia, Myelomonocytic, Chronic

540 studies on the registry are indexed under Leukemia, Myelomonocytic, Chronic; 69 are open to participants now.

Browse Leukemia, Myelomonocytic, Chronic studies →

Open to participants now

48 of the 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 63 Leukemia, Myelomonocytic, Chronic studies recruiting now, 47 (75%) set no upper age limit and 7 (11%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 441 studies in Leukemia, Myelomonocytic, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are:

  • Does pacritinib improve disease control compared to hydroxyurea?
  • What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia.

Participants will be randomly assigned to receive either pacritinib twice a day or hydroxyurea for up to 48 weeks.

After treatment ends, participants will be followed for up to one year.

Read the detailed description

This is a randomized, multicenter, open-label Phase 2 clinical trial evaluating the efficacy and safety of pacritinib compared to hydroxyurea in adult participants with advanced proliferative chronic myelomonocytic leukemia (CMML). Approximately 66 participants will be randomized in a 2:1 ratio to receive either pacritinib 200 mg twice daily (n=44) or hydroxyurea (n=22) for up to 48 weeks. Randomization will be stratified based on prior therapy (i.e., prior use of hydroxyurea or hypomethylating agents vs. no prior therapy).

The study includes:

  • A 28-day screening period
  • A 48-week treatment period
  • A 30-day post-treatment follow-up
  • A survival follow-up phase lasting approximately one year after randomization Participants receiving pacritinib who are not deriving benefit by Week 24, as assessed by the treating physician, will discontinue treatment. Participants in the hydroxyurea arm who are not deriving benefit by Week 24-or who experience non-leukemic disease progression-may switch to pacritinib for the remainder of the treatment period, provided they meet predefined "Safe to Switch" criteria.

Participants who discontinue study therapy due to toxicity, disease progression, or other protocol-defined criteria will enter survival follow-up to monitor overall survival, event-free survival, leukemic-free survival, and receipt of allogeneic hematopoietic stem cell transplant. Data will be collected at least every three months until death, hematopoietic stem cell transplant, or leukemic transformation.

An independent data monitoring committee will oversee safety, with the first review after enrollment of \~18 participants and subsequent reviews approximately every 6 months.

03

Conditions studied

  • Leukemia, Myelomonocytic, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of CMML-1 (5th WHO classification), with \<10% bone marrow blasts on morphology and \<5% peripheral blood blasts.
  • Proliferative disease, defined as white blood cell count ≥13 × 10⁹/L.
  • Advanced disease, defined as at least one of the following features during screening: spleen palpable ≥5cm below the lower costal margin in the midclavicular line; TSS ≥20; or count \<100 × 10⁹/L. For participants in whom spleen palpation is not feasible, an ultrasound exam may be performed for assessment of spleen craniocaudal length (length ≥12 cm by ultrasound is considered splenomegaly).
  • performance status ≤2.
  • Adequate organ function: and ALT ≤3 × , total ≤4 × ULN (≤8 × ULN in participants with Gilbert's syndrome), >30 mL/min, ≥0.5 × 10⁹/L, PT and ≤1.5 × ULN.
  • Women of must have a negative serum pregnancy test within 7 days prior to enrollment and, along with male participants, must agree to use a highly effective method of from the first dose through 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Active diagnosed within the past 2 years, except for curatively treated non-invasive cancers (e.g., basal/squamous cell skin cancer, low-risk prostate cancer on stable endocrine therapy with PSA stable ≥3 months).
  • hematopoietic stem cell transplant within 12 months prior to enrollment, or requiring therapy within 6 months before enrollment.
  • Likely to undergo allogeneic hematopoietic stem cell transplant within 6 months, per investigator assessment.
  • Prior systemic treatment with any JAK inhibitor.
  • Treatment with hypomethylating agents or cytotoxic chemotherapy (excluding hydroxyurea) within 28 days prior to enrollment.
  • Participation in another interventional study or use of experimental therapy within 28 days or 5 half-lives, whichever is longer.
  • Use of hematologic support drugs within 28 days prior to enrollment. Supportive care permitted.
  • Use of strong inhibitors or inducers within 14 days or 5 half-lives before enrollment, whichever is shorter.
  • Use of systemic anticoagulants or antiplatelets (except aspirin ≤100 mg/day) within 14 days prior. Therapeutic anticoagulation allowed if stable for ≥90 days without bleeding events.
  • Grade ≥2 bleeding within 3 months prior to enrollment, unless due to a reversible cause (e.g., trauma, surgery).
  • >450 ms (men) or >470 ms (women); QTcF up to 480 ms allowed if QRS >100 ms. QTcF may be repeated if affected by reversible factors.
  • CTCAE Grade ≥3 cardiac event within 3 months before enrollment.
  • Symptomatic heart failure with limitations on ordinary activity.
  • Uncontrolled infection at study entry.
  • Moderate/severe hepatic impairment ( B or C), or active viral hepatitis:
  • : Exclude if HBsAg+ or HBV DNA detectable. HBV antiviral therapy allowed if HBV DNA undetectable.
  • : Allowed if HCV Ab+ but RNA negative.
  • Uncontrolled or detectable viral load while on antiretrovirals.
  • Known to pacritinib or its (microcrystalline cellulose, polyethylene glycol, magnesium stearate).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Pacritinib

    Pacritinib 200 mg twice daily

    Drug: Pacritinib

  • Active comparator
    Hydroxyurea

    Hydroxyurea at doses up to 4 g daily

    Drug: Hydroxyurea

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical benefit at Week 24, defined as achieving erythroid response in the absence of leukemic transformation.

    For participants with baseline hemoglobin \<10 g/dL, response is defined as either a ≥1.5 g/dL hemoglobin increase lasting ≥8 weeks without red blood cell transfusion, or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of red blood cell transfusion independence, excluding transfusions given for pretreatment Hb ≤8.5 g/dL. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  2. Clinical benefit at Week 24, defined as achieving platelet response in the absence of leukemic transformation.

    For participants with baseline platelet counts \<100 × 10⁹/L, response is defined as one of the following: an increase to ≥20 × 10⁹/L and by ≥100% for ≥8 weeks without platelet transfusion (if baseline \<20 × 10⁹/L); an increase of ≥30 × 10⁹/L for ≥8 weeks without transfusion (if baseline 20-\<100 × 10⁹/L); or, if transfusion-dependent at baseline (≥4 units in the 8 weeks pre-enrollment), achieving ≥8 weeks of platelet transfusion independence. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  3. Clinical benefit at Week 24, defined as achieving neutrophil response in the absence of leukemic transformation.

    For participants with baseline ANC ≤1 × 10⁹/L, response is defined as either an increase to \>0.5 × 10⁹/L and by ≥100% for ≥8 weeks without myeloid growth factors (if baseline ANC ≤0.5 × 10⁹/L), or an increase by ≥50% for ≥8 weeks without myeloid growth factors (if baseline ANC \>0.5 to ≤1 × 10⁹/L). Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  4. Clinical benefit at Week 24, defined as achieving spleen response in the absence of leukemic transformation.

    For participants with baseline spleen ≥5 cm below the left costal margin (midclavicular line), spleen response is defined as a ≥35% reduction in spleen volume at endpoint assessment by MRI or CT. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  5. Clinical benefit at Week 24, defined as achieving symptom response in the absence of leukemic transformation.

    Among participants with baseline Total Symptom Score (TSS) ≥20 per the MPN-SAF TSS: achieving ≥50% TSS reduction from baseline at the time of endpoint assessment. Leukemic transformation is defined as ≥20% blasts or blast equivalents in the peripheral blood or bone marrow biopsy, or development of granulocytic sarcoma.

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

Secondary outcomes

  1. Clinical benefit at any time, defined as achieving at least one of the primary endpoint clinical benefit response criteria at any time on study.

    Time frame: Measured from the start of study treatment to the end of treatment, for up to 48 weeks.

  2. Achieving response at Week 24 and 48 according to the IWG 2015 criteria), including the following subtypes: complete response, complete cytogenetic remission, partial remission, marrow response

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  3. Duration of response for primary endpoint (clinical benefit by Week 24)

    Time frame: Measured from Week 24 through the end of treatment, up to 48 weeks.

  4. Event-free survival

    Event-free survival is defined as the time without death from any cause, transformation to AML (including granulocytic sarcoma), or disease progression after ≥3 cycles (Week 12), including CMML-1 to CMML-2 with ≥5% absolute blast increase or worsening splenomegaly.

    Time frame: Measured from the start of study treatment to the end of treatment, for up to 48 weeks.

  5. Leukemia-free survival, where events include death from any cause or transformation to AML (including granulocytic sarcoma)

    Time frame: Measured from the start of study treatment to the end of treatment, for up to 48 weeks.

  6. Overall survival

    Time frame: Measured from the date of initiating study treatment to the date of death from any cause, assessed up to 24 months.

  7. Incidence of allogeneic hematopoietic stem cell transplant.

    Time frame: Measured from the date of initiating study treatment to the date of allogeneic hematopoietic stem cell transplant., assessed for up to 24 months

  8. Adverse events and laboratory abnormalities as graded by NCI CTCAE v5.0.

    Time frame: From the start of the adverse event collection period through 30 days following the last dose of study treatment.

  9. Change in arterial blood pressure measured in mmHg.

    Time frame: From the start of the study treatment through 30 days following the last dose of study treatment.

  10. Change in pulse rate measured in beats per minute.

    Time frame: From the start of the study treatment through 30 days following the last dose of study treatment.

  11. Change in respiratory rate measured in breaths per minute.

    Time frame: From the start of the study treatment through 30 days following the last dose of study treatment.

  12. Change in corrected QT interval measured in milliseconds using 12-lead electrocardiogram.

    Time frame: From the start of the study treatment through 30 days following the last dose of study treatment.

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.

Of 69 phase 2 interventional studies under Leukemia, Myelomonocytic, Chronic, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 110. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 24, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Dec 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07033598
Lead sponsor
Theradex
Collaborators
MDS/MPN International Working Group (UK Sponsor), Sobi, Inc., H. Lee Moffitt Cancer Center and Research Institute
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Jan 1, 2026
Primary completion
Jul 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Zach Albaugh
Contact
zalbaugh@theradex.com
Melissa Fischer
Contact
mfischer@mdsmpn.org

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pacritinib

Start the discussion